Trends in Intrahepatic and Bile Duct Cancers in the United States from 1999 to 2023 - Report - MDSpire

Trends in Intrahepatic and Bile Duct Cancers in the United States from 1999 to 2023

  • By

  • Samuel W. Berg

  • Taylor Billion

  • Abubakar Tauseef

  • April 29, 2026

  • 0 min

Share

Clinical Report: Trends in Intrahepatic and Bile Duct Cancers in the US

Overview

This report examines the rising mortality rates associated with liver and intrahepatic bile duct cancers in the United States from 1999 to 2023. Significant demographic disparities were identified, particularly among American Indian and Alaskan native populations, while a decrease was observed in Asian and Pacific Islander groups.

Background

Liver and intrahepatic bile duct cancers are responsible for a notable percentage of cancer-related deaths in the U.S., with a low 5-year survival rate. The increasing incidence and mortality rates highlight the need for improved screening and treatment strategies, especially given the challenges in early diagnosis. Understanding demographic trends is crucial for targeting healthcare resources effectively.

Data Highlights

Demographic GroupMortality Trend
American Indian and Alaskan NativeHigher mortality rates
Asian and Pacific IslanderDecrease in mortality
MalesGreater mortality trend
FemalesLower mortality trend
RegionsSouth and West have highest AAMR

Key Findings

  • Overall higher mortality rates in American Indian and Alaskan native populations.
  • Decrease in mortality rates among Asian and Pacific Islander populations.
  • Significantly greater mortality trends in males compared to females.
  • Regions with the highest age-adjusted mortality rates are the South and West.
  • Intrahepatic bile duct cancers have seen a 4.36% increase in incidence over the last decade.

Clinical Implications

Healthcare providers should focus on targeted screening and diagnostic strategies for high-risk populations, particularly among American Indian and Alaskan native individuals. Additionally, awareness of the demographic trends can guide resource allocation and policy-making to improve outcomes in liver and intrahepatic bile duct cancer management.

Conclusion

The rising mortality rates from liver and intrahepatic bile duct cancers necessitate urgent attention to screening and treatment strategies, particularly for vulnerable populations. Continued research and policy efforts are essential to address these disparities effectively.

References

  1. Frontiers in Oncology, 2026 -- Burden of liver cancer from 1990 to 2021 and modelled projection to 2040: insights from the global burden of disease study 2021
  2. The ASCO Post, 2023 -- Patterns in Early-Onset Cancer Incidence in the United States From 2010 to 2019
  3. The New Gastroenterologist, 2025 -- Declining Mortality Rates Associated with Chronic Hepatitis C Infection
  4. Journal of Gastroenterology -- Analysis of the Incidence and Trends of Uncommon Hepatobiliary and Pancreatic Cancers from a National Cancer Database
  5. Hepatology -- Critical Update: AASLD Practice Guidance on Hepatocellular Carcinoma
  6. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - PMC
  7. Hepatology
  8. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - PMC
  9. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma - ScienceDirect

Original Source(s)

Related Content